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Abstract
Background: Regulators and payers have to strike a balance between the needs of the patient and
the optimal allocation of resources. Drugs indicated for rare diseases (orphan medicines) are a
special group in this context because of their often high per unit costs. Our objective in this pilot
study was to determine, for drugs used in an outpatient setting, how utilisation of centrally
authorised drugs varies between countries across a selection of EU member states.
Methods: We randomly selected five orphan medicines and nine other drugs that were centrally
authorised in the European Union between January 2000 and November 2006. We compared
utilisation of these drugs in six European Union member states: Austria, Denmark, Finland,
Portugal, The Netherlands, and Sweden. Utilisation data were expressed as Defined Daily Doses
per 1000 persons per year. Variability in use across countries was determined by calculating the
relative standard deviation for the utilisation rates of individual drugs across countries.
Results: No association between orphan medicine status and variability in use across countries
was found (P = 0.52). Drugs with an orphan medicine status were more expensive and had a higher
innovation score than drugs without an orphan medicine status.
Conclusions: The results show that the variability in use of orphan medicines in the different
health care systems of the European Union appears to be comparable to the other newly
authorised drugs that were included in the analysis. This means that, although strong heterogeneity
in access may exist, this heterogeneity is not specific for drugs with an orphan status.
Background
In every health care system regulators and third party pay-
ers have to strike a balance between the needs of the indi-
vidual patient and the optimal allocation of resources. For
new pharmaceuticals, national regulations and traditions
are important determinants for how individual drugs are
embedded in the system. This embedding process is sub-
ject to multiple factors that require a number of decisions.
For example, payers have to decide whether or not the
drug should be reimbursed and under what conditions.
For most drugs, the outcome of this process is determined
by the interactions between an internationally organised
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supply side, represented by pharmaceutical companies,
and national regulators who manage the demand side
within their health care system. The positions of each
party are determined by a large number of parameters,
such as specific country characteristics, the economic posi-
tion of the pharmaceutical company, political develop-
ments, or scientific discoveries.
Studying the variation in uptake of drugs across health
care systems can provide information on how the out-
come of the embedding process in the form of access to,
and use of, new therapies differs from one country to
another. Drugs developed specifically for the treatment of
rare diseases ('orphan medicines') are a group of special
interest in this context because of their often high per unit
costs and for usually not being able to fulfil the standard
cost-effectiveness criteria that are used in reimbursement
decisions [1,2]. This may lead to drugs that are indicated
for the treatment of rare diseases being more susceptible
to variation in access and use than other drugs, thus lead-
ing to a stronger heterogeneity in use. The possibly spe-
cific problems with the availability of drugs for rare
diseases, has been high on the agenda of organisations
such as the European Organisation for Rare Diseases
(Eurordis) for several years [3,4].
At the European Union (EU) level, the European Medi-
cines Agency (EMEA) provides a centralised market
authorisation procedure for new medicinal products, with
a harmonised Summary of Product Characteristics
(SmPC) for the whole European Union (EU) since 1995.
Therefore, the EMEA centralised procedure allows the
comparison of the use of drugs in different EU health care
systems for drugs of which the quality, safety and efficacy
were assessed by one and the same institution.
Currently, the centralised procedure is mandatory for bio-
technology drugs and for all medicines intended for the
treatment of HIV/AIDS, cancer, diabetes, neurodegenera-
tive diseases, autoimmune and other immune dysfunc-
tions, and viral diseases. A centralised procedure is
mandatory for orphan medicines (OMs) as well.
Our objective in this pilot study was to determine, for
drugs used in an outpatient setting, how utilisation of cen-
trally authorised drugs varies across a selection of EU
member states. In particular, we were interested in deter-
mining whether drugs that have received an orphan med-
icine status show a higher level of variability in use than
centrally authorised medicines without an orphan medi-
cine status, and consequently are more vulnerable to het-
erogeneity in access and subsequent use.
Methods
Study population
We randomly selected fifteen drugs using SPSS version
13.0 from a list of drugs that were centrally authorised in
the EU between 1 January 2000 and 30 November 2006
and could also be used in the ambulatory setting (list
compiled by the authors). We randomly selected five
OMs: imatinib mesilate (Glivec®), bosentan (Tracleer®),
zinc acetate dihydrate (Wilzin®), nitisinone (Orfadin®)
and sodium oxybate (Xyrem®). In addition, we randomly
selected ten other/non-orphan medicines: levetiracetam
(Keppra®), desloratidine (Aerius®), telmisartan/hydro-
chlorothiazide (Kinzalkomb®), emtricitabine (Emtriva®),
apomorfine (Uprima®), adefovir dipivoxil (Hepsera®),
oxybutinin (Kentera®), pregabalin (Lyrica®), efalizumab
(Raptiva®), abacavir/lamuvidine (Kivexa®).
In our initial selection we also included apomorfine
(Uprima®), but since the market authorisation for this
drug was not renewed in January 2006 and because the
drug was only marketed in a few of the countries in this
study, we excluded it from our final analysis.
We retrieved information about the utilisation of these
drugs in six European Union member states countries:
Austria, Denmark, Finland, Portugal, The Netherlands,
and Sweden. These countries represent a selection of EU
member states from different regions and with different
health care systems, and for which drug utilisation data
for all drugs included in the analysis was available.
Utilisation rates of drugs included in the study
We calculated drug utilisation rates as a measure of uptake
in the health system. We determined utilisation rates for
the year 2006, as this was the latest full calendar year in
the study period.
Utilisation rates were expressed as the number of Defined
Daily Doses (DDD) per 1000 inhabitants per year. The
DDD is a standard dosage measure defined by the World
Health Organisation [5]. If DDDs were not available for a
drug we defined the DDD ourselves based on information
about the average daily dose contained in the official drug
label. If a drug has more than one indication, the DDD is
based on its first main indication in adults.
Variability in use
Between-country variability in use was determined by cal-
culating the relative standard deviation (RSD) for the uti-
lisation rates of individual drugs across countries. This
measure for variability in use was calculated as follows:
100*
Standard deviation of utilization as DDDs/1000 persons/ /year across countries
Average of utilization as DDDs/1000   persons/year across countriesOrphanet Journal of Rare Diseases 2009, 4:27 http://www.ojrd.com/content/4/1/27
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This method for calculating the variability in use was used
elsewhere as well [6]. Utilisation rates equal to zero were
excluded from further analysis.
Innovativeness
Innovativeness of individual drugs was rated according to
a system based on an algorithm designed by Motola et al
[7]. This algorithm divides newly marketed drug in five
classes according to two dimensions of therapeutic inno-
vation; availability of other treatments and the therapeu-
tic effect. Scores for availability of other treatments ranged
from 5 (drugs for diseases without recognised standard
treatment) to 1 (mere technological innovation). Scores
for therapeutic effect ranged from 3 (major benefit on
clinical endpoints or validated surrogate endpoints) to 1
(minor or temporary benefit on some aspects of the dis-
ease). All drugs included in the study were ranked accord-
ing to the two dimensions of innovation with this system.
We calculated the product of both scores as numeric indi-
cator of therapeutic innovation for all products in the
study. Where available, we used a list compiled by Motola
et al. which was available online [8]. For drugs for which
no score was available, the innovativeness was rated inde-
pendently by two of the authors (HH and PS).
Cost
As an indicator for cost differences between drugs we sam-
pled the cost per DDD for each drug in three of the coun-
tries in this study (Denmark, The Netherlands and
Sweden). These were the countries in this study for which
cost information was publicly available. Within each
country, we ranked all 14 drugs according to their cost per
DDD. Based on the average cost per DDD ranking in each
of the countries we determined an overall cost per DDD
rank for each drug. A score of 1 was assigned to the cheap-
est drug; a score of 14 was assigned to the most expensive
drug.
Results
The basic characteristics of the six countries included in
this study are shown in Table 1. This Table also provides
information about the data sources from which the utili-
sation data in this study was retrieved.
Table 1: Characteristics of countries. Source: OECD Health Data 2007 and EuroStat. All data for 2006 unless otherwise indicated.
Austria Finland Netherlands Sweden Denmark Portugal
Population 
(millions) (2006)
8.27 5.26 16.33 9.05 5.43 10.57
Population aged 65 
and over (%)
16.3 15.9 13.8 17.3 15.1 17.0
GDP per capita 
(US Dollar)
34 394 30 911 35 112 32 111 34 110 20 030
Health 
expenditure as a 
share of GDP (%)
10.2 7.5 9.2 9.1 9.1 10.2
Pharmaceutical 
spending per 
capita 
(US Dollar PPP)
409 380 318 351 276 445
Pharmaceutical 
spending 
(% of GDP)
1.2 1.2 1.0 1.1 0.8 2.2
Automatic 
reimbursement for 
all marketed 
productsa
No No No No No No
Pharmacoeconomi
c assessment 
required for 
reimbursement*
Possibly Yes Only for 
innovative 
medicines
Cost-effectiveness 
is one a criterion 
which determines 
reimbursement 
eligibility
Not mandatory, 
sometimes used to 
justify a higher 
price
Only for 
innovative 
medicines
Utilisation data 
source
Claims data of the 
Austrian sickness 
fund 
(PEGASUS-SV)
Ambulatory and 
hospital from the 
Finish National 
Agency for 
Medicines http://
www.nam.fi
Ambulatory data 
from the GIP 
database http://
www.gipdatabank.
nl
Ambulatory data 
from
Apoteket
Ambulatory and 
hospital data from 
the Danish 
Medicines Agency 
http://
www.medstat.dk
Dispensing data of 
ambulatory care 
nationwide and 
IMS for hospital 
data 
(SIC-MED system)
Data type Reimbursement Dispensing Reimbursement Dispensing Dispensing Dispensing
aPharmaceutical Pricing and Reimbursement Information (PPRI) report, the PPRI Network 2008. See http://ppri.oebig.at/
GDP: Gross Domestic ProductOrphanet Journal of Rare Diseases 2009, 4:27 http://www.ojrd.com/content/4/1/27
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Table 2 provides an overview of the fourteen drugs
included in the final analysis. For each drug, the date of
EU market authorisation, the indication, the DDD used in
the analysis, the innovation score, the cost per DDD rank-
ing, and the RSD for the utilisation rate across the coun-
tries are reported.
In Figure 1 we have displayed the relationship between,
cost, innovativeness and variability in use for each of the
drugs. The innovativeness score for each drug is depicted
on the x-axis, the y-axis shows the cost ranking, while the
bubble sizes denotes variability in use. The dark gray bub-
bles are orphan medicines, the light gray bubbles are
drugs without an orphan medicine status. The Figure can
be divided in roughly four quadrants. The lower left quad-
rant contains drugs with a low score for innovativeness
and low treatment costs. The upper right quadrant con-
tains drugs with a high innovativeness score and high
treatment costs. As the Figure shows, drugs with an
orphan medicine status are, in general, more expensive
and have a higher innovation score than drugs without an
orphan medicine status. An independent samples t-test
(alpha = 0.05; SPSS version 13.0) showed that there is no
Table 2: Overview of the drugs included in the study
Active 
substance
Market 
authorisatio
n date
Indication DDD Innovation 
score
Cost per 
DDD 
ranking
RSD for 
utilisation
Number of 
countries with 
> 0 utilisation
With orphan 
status
imatinib 11 Nov 2001 Chronic myeloid leukaemia, acute 
lymphoblastic leukaemia, 
myelodysplastic/myeloproliferative 
diseases, advanced 
hypereosinophilic syndrome, 
chronic eosinophilic leukaemia, 
metastatic malignant 
gastrointestinal stromal tumours, 
dermatofibrosarcoma protuberans
400 mgb 12 12 7.2% 5
bosentan 15 May 2002 Pulmonary arterial hypertension 0.25 g 6c 14 37.1% 6
zinc acetate 
dehydrate
13 Oct 2004 Wilson's disease. 0.15 g 15 6 44.9% 4
nitisinone 21 Feb 2005 Hereditary tyrosinemia type 1 20 mg 15c 13 112.1% 4
sodium 
oxybate
13 Oct 2005 Cataplexy in narcolepsy patients. 7.5 g 10c 11 127.6% 3
Without 
orphan 
status
levetiracetam 29 Sep 2000 Epilepsy 1.5 g 8 5 29.1% 6
telmisartan/
hydrochloroth
iazide
19 Apr 2002 Essential hypertension. 65 mga 9c 2 110.0% 4
emtricitabine 24 Oct 2003 HIV-1 infected adults and children 
in combination with other 
antiretroviral agents.
0.2 g 9c 7 142.5% 5
adefovir 
dipivoxil
6 Mar 2003 Chronic Hepatitis B 10 mg 12 9 89.2% 5
oxybutinin 26 Feb 2004 Symptoms of urge incontinence 
and/or increased urinary 
frequency.
15 mg 2 3 90.5% 6
pregabalin 6 Jul 2004 Peripheral and central neuropathic 
pain
0.3 g 10c 4 68.9% 6
efalizumab 20 Sep 2004 Moderate to severe chronic plaque 
psoriasis
10 mg 8c 10 53.5% 5
abacavir/
lamuvidine
17 Dec 2004 Combination therapy for Human 
Immunodeficiency Virus (HIV).
0.9 ga 9c 8 109.9% 5
desloratidine 21 Sep 2000 Allergic rhinitis and chronic 
idiopathic urticaria
5 mg 3 1 41.1% 6
a Combination preparation, DDD determined according to WHO guidelines. b DDD determined by authors based on literature, not WHO-CC. c 
Innovativeness score determined by authors based on algorithm by Motola et al.
RSD: Relative Standard Deviation, DDD: Defined Daily DoseOrphanet Journal of Rare Diseases 2009, 4:27 http://www.ojrd.com/content/4/1/27
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association between variability in use and orphan medi-
cine status (P = 0.52).
Conclusions
The results from this pilot study show that the variability
in use of orphan medicines in the different health care sys-
tems of the European Union appears to be comparable to
the other newly authorised drugs that were included in
the analysis. This means that, although strong heterogene-
ity in access may exist, this heterogeneity is not specific for
orphan medicines. Therefore, orphan medicines may not
constitute a 'special' group in this respect; heterogeneity
may be an intrinsic aspect of the drug market in the Euro-
pean Union as a whole.
Orphan medicines rated generally higher on our innova-
tiveness rating system than drugs without an orphan med-
icine status. The requirements for an orphan status are
strongly congruent with the requirements for an 'Impor-
tant' innovation in the model of Motola et al. One of the
requirements for a drug to be eligible for an orphan med-
icine status is that "there exists no satisfactory method of
diagnosis, prevention or treatment of the condition in
question that has been authorised in the Community or,
if such method exists, that the medicinal product will be
of significant benefit to those affected by that condition
[9]." Therefore, the concept of innovativeness in this study
should be understood within the constraints of the defini-
tion used.
The outcome of the embedding process of a drug in clini-
cal practice, and the ensuing utilisation, is the result of the
interactions between drug manufacturers and regulators.
Sources of variability exist at each of the stages of the
embedding process. In the first place, the structural char-
acteristics of each health care system vary significantly in,
amongst others, population, the legal framework, budg-
ets, prescribing habits by physicians and disease preva-
lence. Some of these sources of variability are described in
Table 1.
Innovativeness versus cost matrix for centrally authorised drugs with and without orphan status Figure 1
Innovativeness versus cost matrix for centrally authorised drugs with and without orphan status. X-axis depicts 
therapeutic innovativeness, while the Y-axis shows average cost per DDD rank. The size of the bubbles describes the variabil-
ity in use across the countries in the study. Exact locations in the matrix are shown by dots within the bubbles. No statistically 
significant difference in variation in use was found (P = 0.52).
Orphanet Journal of Rare Diseases 2009, 4:27 http://www.ojrd.com/content/4/1/27
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Second, the role of the companies and regulators differs
from case to case. For example, the international scope of
drug manufacturers may lead to strategic decisions at the
company level not to spend resources on marketing and
reimbursement in a particular market. Also, the intricacies
of price setting systems may make it beneficial to enter
national markets in a particular order. Furthermore, for
smaller companies, it may not be possible to market a
drug product in all countries at the same time and a com-
pany may decide to introduce the product on the Euro-
pean market in phases.
Third, regulators in each country face unique inputs that
may influence their assessment of an individual drug,
such as constraints in (drug) budgets, the influence of
patient organisations, or political pressure.
The interactions between different regulators and compa-
nies in the context of the structural characteristics of each
country can lead to a wide variety of outcomes, which are
designed to influence actual use in a different way. As the
results from this pilot study indicate neither cost per
DDD, nor innovativeness or an orphan status influences
the variability in use between the countries in the study.
Certain limitations apply to this pilot study. Given the
small sample sizes, it is very difficult to disentangle the
specific contributions of innovativeness and cost to the
variability in use. In addition, when including per unit
treatment costs in our analysis, we used a method of rank-
ing drugs according to their cost per DDD which only
included costs in three countries, thus disregarding costs
in the three other countries in the study. However, it is
unlikely that relative costs in the other three countries in
the study would differ significantly. We have no reason to
believe that the ranking based on relative cost per DDD
would show large variations when these other countries
would have been included as well.
Furthermore, we only looked at the national level in this
study and did not take regional variation into considera-
tion. Access to, and use of, drugs may show large regional
variability, for example, depending on policy and budget
considerations of individual hospitals or insurance com-
panies [10].
Another limitation is that we did not include the indica-
tion of the drugs into our analysis. For some of the pri-
mary indications of drugs included in this study the
prevalence may vary across countries, thus leading to an
overestimation of the RSD measure for the utilisation of
these drugs. Also, for several orphan medicines, such as
zinc acetate, compounded alternatives may be available,
which would make our measurement of the utilisation of
this drug an underestimate in some countries. Further-
more, for some of the drugs alternative treatments may be
available.
The data sources used in this study consisted of reimburse-
ment and dispensing data. Therefore, our results may have
been influenced by differences between reimbursement
and utilisation within countries or by differences by the
location of data collection (public pharmacy, hospital
pharmacy or both). As this limitation is an inherent char-
acteristic of the data, we have indicated the source of our
data in Table 2. This also indicates that there is a need for
a harmonised method of data collection on drug utilisa-
tion within Europe.
Finally, the countries included constitute a selection of
smaller and medium sized EU member states. Results
from this pilot study should therefore be extrapolated to
other EU member states with caution; regulatory systems
and GDP may vary significantly from the countries
included in the study. For two groups it is especially
important to note their absence. Firstly, none of the large
member states such as Germany, France and the UK are
included in the analysis. Furthermore, countries that
joined the EU on or after 1 May 2004 are also not
included. The Eurordis survey on orphan medicines that
was mentioned earlier4, specifically mentions newer EU
countries as countries with potentially low availability of
orphan medicines. These countries may well have specific
challenges with access and use of newly authorised drugs.
Overall, we believe that this study provides interesting
preliminary data that warrants future investigations in
which the methodological constraints of this study can be
addressed.
In conclusion, we found that orphan medicines show no
larger variability in use than drugs without an orphan
medicine status. Therefore, heterogeneity in variability
may be a feature of the drug market in the EU in general,
and not restricted to one class of drugs. Future studies
looking at access issues should also take the actual utilisa-
tion into account for a comprehensive assessment of this
topic.
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